developmentstoday

Ask DT AI Audio Brief Videos Podcast +

Ask DT AI Audio Brief Videos Podcast

HomeTagscancer-research

#cancer-research

All articles tagged with "cancer-research"

Company

About Us
Advertise
Contact
Editorial Policy

Legal

Terms of Service
Privacy Policy
Cookie Policy
AI & Ethics Policy
Do Not Sell My Info
FAQ
Archive
Site Map

Discover

Newsletter
Ask DT AI
Audio Brief
Videos
Podcast
DT Premium

Connect

Twitter / X
Facebook
LinkedIn
YouTube
Instagram
TikTok
Flipboard
RSS Feed

© 2026 Developments Today. All rights reserved.

cancer-research Articles | Developments Today

Reprogramming tumor microenvironment could improve prospects for treatment of pancreatic cancer

CD44 Target May Help Rework Pancreatic Cancer Defenses

Pancreatic tumor microenvironments can make up to 90% of tumor mass.
CD44 was found to intensify fibroblast-activating signals.
CD44 inactivation reduced tumor size in a mouse model.

DE

DT Editorial Team·Oct 24, 2026·via medicalxpress.com

More in Health→

Researchers show how leukemia cells 'hide' from treatment

Study maps how leukemia cells switch survival signals

Researchers tested a detailed CLL signaling model with cells from patients.
Some CLL cells may use Toll-like receptor signaling when BCR signaling is blocked.
The work may help investigate relapse cases without detectable resistance mutations.

DE

DT Editorial Team·Oct 23, 2026·via medicalxpress.com

More in Health→

Liver tumors form without detectable driver mutations in mice, revealing epigenetic route

Epigenetic pathway offers a new model for mutation-free liver tumors

The study describes a YAP1–TEAD–TET1 pathway in hepatocellular carcinoma without canonical driver gene mutations.
TET1-mediated DNA demethylation activated multiple oncogenes in the reported model.
Suppressing TET1 reduced tumor formation in mice.
Human liver-disease data supported the pathway’s relevance, according to the source.

DE

DT Editorial Team·Oct 22, 2026·via medicalxpress.com

More in Health→

Pancreatic cancer study highlights body's natural molecules as potential treatment tools

Pancreatic Cancer Study Points to microRNA Treatment Targets

Texas A&M researchers increased miR-15a and miR-16 in PDAC cells.
The increase reduced protein synthesis and slowed cell growth.
Higher tumor levels of the microRNAs were associated with longer survival in the study summary.
The findings are preclinical and require further testing before any clinical use.

DE

DT Editorial Team·Oct 21, 2026·via medicalxpress.com

More in Health→

Marginalization, lack of primary care provider increase risk of early death from metastatic breast cancer

Ontario study links inequity and primary care gaps to early metastatic breast cancer deaths

Ontario researchers analyzed 4,004 people treated for de novo metastatic breast cancer from 2010 to 2019.
Twenty-three percent died within six months of diagnosis.
Older age, chronic illness, housing and income marginalization, and lack of a primary care provider were associated with higher early-death risk.

DE

DT Editorial Team·Oct 19, 2026·via medicalxpress.com

More in Health→

USC scientists discover how to create a never-ending supply of cancer-fighting cells

USC study explores renewable engineered immune cells for cancer

USC researchers engineered granulocyte-monocyte progenitors, an immature immune-cell type.
The cells expanded in the laboratory and generated new immune cells after establishing in mouse bone marrow.
In mice, the approach slowed blood cancers and solid tumors; human clinical effectiveness remains unproven.

DE

DT Editorial Team·Oct 16, 2026·via sciencedaily.com

More in Science→

Study finds a lower cancer risk after obesity surgery regardless of age or sex

Obesity Surgery Linked to Lower Cancer Risk Across Ages and Sexes

Study included more than 780,000 people with obesity in Sweden, Denmark and Finland.
Nearly 100,000 participants had undergone bariatric surgery.
Surgery was associated with an approximately 20% lower risk of obesity-related cancer.
The association was similar across age groups and sexes.

DE

DT Editorial Team·Oct 15, 2026·via medicalxpress.com

More in Health→

Continuously evolving cells help pancreatic cancer evade treatment and spread

Pancreatic Cancer Study Maps How Tumors Evolve

Researchers analyzed nearly 500,000 individual cells from pancreatic tumors collected from dozens of patients.
The study found genetically distinct clones associated with treatment resistance and rapid spread.
Blocking MYC in basal tumor cells shifted them toward a less aggressive state and exposed them to more immune cells.

DE

DT Editorial Team·Oct 13, 2026·via medicalxpress.com

More in Health→

Ancient viral DNA helps embryonic stem cells grow—and cancer hijacks the same switch

Ancient Viral DNA Helps Embryos Grow—and Cancer Hijacks the Same Switch

HERVH, a non-infectious human endogenous retrovirus, acts as a switch that turns on the calbindin gene.
Calbindin removes calcium from cells and is normally found in brain and kidney tissue where calcium must be tightly controlled.
Three years ago researchers found a specific form of calbindin in lung cancer cells helped them survive by preventing ageing.
Judith Pape and Kathy Niakan's team tested the effect of removing calbindin or HERVH in human embryonic stem cells.

DE

DT Editorial Team·Oct 8, 2026·via medicalxpress.com

More in Health→

Mitochondrial DNA levels reveal links to tumor growth and chemotherapy-related gene activity

Mitochondrial DNA Copy Number Tied to Tumor Growth and Chemotherapy Gene Activity

New research in The FEBS Journal found a correlation between mtDNA copy number and the extent of genetic mutations in cancer cells.
Increased mtDNA copy number showed a signature of compensation for impaired mitochondrial function in cancer cells.
Variation in mtDNA copy number was linked to expression of genes associated with chemotherapy response and other aspects of cancer.
High mtDNA copy number was associated with genes that support tumor growth and survival.

DE

DT Editorial Team·Oct 7, 2026·via medicalxpress.com

More in Health→

Targeting WRN helicase in MSI-H tumors: Synthetic lethality, small molecule discovery, and therapeutic perspectives - ScienceDirect (via www.sciencedirect.com)

WRN Inhibitor Exploits Synthetic Lethal Weakness in MSI Cancers

A phase 1 trial reported in Nature Medicine tested inhibition of the Werner syndrome helicase (WRN) in cancers with microsatellite instability.
The approach relies on synthetic lethality: MSI tumors already lack mismatch repair, and blocking WRN removes a second pathway they depend on.
WRN is a helicase involved in DNA replication, repair, and genome stability, and MSI cells appear more reliant on it than healthy cells.
Phase 1 studies primarily establish safety, tolerability, dosing and preliminary target engagement rather than proven efficacy.

DE

DT Editorial Team·Sep 29, 2026·via nature.com

More in Health→

Scientists find the gene that drives T-cell exhaustion, revealing new strategy to improve immune responses

St. Jude Scientists Identify ZMYND8 Gene Driving T-Cell Exhaustion

St. Jude Children's Research Hospital scientists published in Nature that the gene ZMYND8 is a major regulator of CD8+ T-cell exhaustion.
ZMYND8 normally brakes genes such as the IL-2 receptor gene Il2ra, but chronic infections and some cancers co-opt it to shut down T-cell activation.
Deleting Zmynd8 improved CD8+ T-cell function against tumors and chronic infections, and may work synergistically with immunotherapy.
The finding could help overcome immunotherapy's limited success against many pediatric solid tumors, though therapeutic translation needs further study.

DE

DT Editorial Team·Sep 24, 2026·via medicalxpress.com

More in Health→

Graphic of a Y chromosome

Y Chromosome Loss Could Be the First Sign of Cancer, Study Finds

A University of Arizona-led investigation links mosaic loss of the Y chromosome to the development of carcinomas, calling it a new hallmark of pending cancer.
About 40% of men in their 70s have tissues that have lost the Y chromosome; by their 90s the figure approaches 60%.
The loss creates a mosaic effect, with each affected cell forming its own patch of unique tissue within the body.
Mosaic Y loss has previously been associated with chronic kidney disease, fibrosis and an increased risk of severe COVID-19.

DE

DT Editorial Team·Sep 21, 2026·via newatlas.com

More in Health→

An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation | Nature Medicine (via www.nature.com)

Nature Medicine Issues Expression of Concern on EZH2 Cancer Study

Nature Medicine published an Editorial Expression of Concern dated 18 September 2026 for a paper on SWI/SNF-mutant cancers and EZH2.
The notice is indexed under DOI 10.1038/s41591-026-04708-9 and does not by itself constitute a retraction or a finding of misconduct.
The paper's title concerns two central topics in cancer epigenetics: the SWI/SNF chromatin-remodelling complex and the enzyme EZH2.
An expression of concern signals to readers that a paper's findings should be treated as provisional pending resolution.

DE

DT Editorial Team·Sep 18, 2026·via nature.com

More in Health→

AACR's annual cancer progress report highlights promising advances for patients

AACR Cancer Progress Report 2026 Highlights AI, Liquid Biopsy and Vaccines

The AACR released the 16th edition of its Cancer Progress Report, covering cancer incidence, mortality and survivorship.
The report links progress to federal research support from the NIH, NCI, FDA and CDC.
It highlights advances in prevention, detection, treatment and survivorship, plus emerging tools such as AI, liquid biopsy, cancer vaccines and RNA medicines.
Patient stories illustrate the real-world impact of cancer research.

DE

DT Editorial Team·Sep 16, 2026·via medicalxpress.com

More in Health→

Advanced optical imaging reveals hidden activity in blood immune cells

Advanced Optical Imaging Reveals Hidden Metabolic Activity in Blood Immune Cells

Researchers used optical metabolic imaging (OMI) to measure metabolic activity in individual immune cells within unmodified PBMC samples.
OMI is label-free and nondestructive, relying on natural fluorescence of NADH and FAD.
The technique can distinguish different metabolic states, providing functional insight beyond cell type identification.
This approach could improve monitoring of immune-related diseases and guide CAR T-cell therapy development.

DE

DT Editorial Team·Sep 7, 2026·via phys.org

More in Science→

Biological changes in firefighters' urine and blood seen 24 hours after fighting a fire

Firefighters show rapid biomarker shifts after fire exposure, study finds

UTHealth Houston researchers analyzed blood and urine from 30 firefighters before and after fire exposure.
Urine showed 75 significantly altered proteins after exposure, compared with 10 in blood serum.
Several altered proteins were linked to cancer-related pathways, suggesting immediate cellular stress after firefighting.

DE

DT Editorial Team·Aug 25, 2026·via medicalxpress.com

More in Health→

Where women live may influence ovarian cancer survival, especially among Black women

Study links neighborhood vulnerability to ovarian cancer survival gaps

Researchers found women in socially vulnerable communities faced a 20% higher risk of death after an ovarian cancer diagnosis.
The study also found Black women faced a 45% higher risk of death than white women.
Authors say neighborhood conditions may help explain persistent racial disparities in ovarian cancer survival.

DE

DT Editorial Team·Aug 10, 2026·via medicalxpress.com

More in Health→

Cancer-fighting chewing gum cuts HPV levels by up to 93%

Experimental Chewing Gum Reduced HPV in Oral Cancer Study

A University of Pennsylvania team tested a bioengineered chewing gum against microbes linked to head and neck cancer.
In patient-derived oral samples, gum extracts reduced HPV by 93% in saliva and 80% in oral rinse samples.
The engineered gum also nearly eliminated two harmful bacterial species while preserving beneficial mouth bacteria.

DE

DT Editorial Team·Aug 4, 2026·via sciencedaily.com

More in Science→

$FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial - Nature Medicine$

Phase 1 trial suggests cevostamab could widen options in heavily pretreated multiple myeloma

A phase 1 trial tested cevostamab in 324 patients with relapsed or refractory multiple myeloma.
Most participants had heavily pretreated disease, and nearly half had prior BCMA-targeted therapy.
The drug produced a 42.1% objective response rate and a median response duration of 11.2 months.
The maximum tolerated dose was not reached, though serious adverse events were common.

DE

DT Editorial Team·Jul 25, 2026·via nature.com

More in Health→

1
2
3
Next